Financial PerformanceInstrument revenue was down 39% and placements remain depressed with only 13 in the quarter, below estimates and previous records.
Market And Industry ConditionsManagement cites industry weakness likely to persist, with constraints on capital spending from academic and discovery customers affecting the company.
Regulatory And Policy ImpactPreliminary Clinical Lab Fee Schedule determinations for new codes were worse than expected for neuro diagnostics, negatively impacting the outlook for tests like blood-based pTau-217.